Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study

Area of Science:

• Infectious Diseases
• Pulmonology
• Clinical Trials

Background:

• Limited research exists on Methicillin-resistant Staphylococcus aureus (MRSA) eradication due to small patient numbers and varied treatment protocols.
• Previous studies lacked standardized therapeutic approaches, hindering definitive conclusions on MRSA eradication efficacy.

Purpose of the Study:

• To evaluate the efficacy of an early eradication treatment for new-onset Methicillin-resistant Staphylococcus aureus (MRSA) infection.
• To compare an active treatment group receiving rifampicin and trimethoprim/sulfamethoxazole with an observational group.

Main Methods:

• A randomized multicenter trial involving patients with new-onset MRSA infection.
• The active arm received 21 days of oral rifampicin and trimethoprim/sulfamethoxazole.
• Assessments included microbiological status, FEV1, BMI, pulmonary exacerbations, and antibiotic use.

Main Results:

• MRSA was eradicated in 63.2% of patients in the active arm versus 38.5% in the observational arm at 6 months.
• A per-protocol analysis revealed a 24.7% higher MRSA clearance rate in the active arm (P = 0.08).
• Favorable tendencies in FEV1 and BMI changes were observed in the active treatment group, though not statistically significant.

Conclusions:

• Early MRSA eradication treatment demonstrated a higher clearance rate compared to observation, despite limited statistical power.
• The study suggests a potential benefit of early intervention for MRSA infections, with positive trends in respiratory and metabolic parameters.